Given the critical role of VEGF in pathological RNV of ROP and the clinical successes of anti-VEGF agents for other neovascular indications, anti-VEGF has generated interests as a therapeutic option for ROP. The gene discussed is VEGFA; the disease is retinopathy of prematurity.